BiotechTube

V591

Phase 1/2Terminated
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Coronavirus Disease (COVID-19)

Conditions

Coronavirus Disease (COVID-19)

Trial Timeline

Aug 27, 2020 → Mar 5, 2021

NCT ID
NCT04498247

About V591

V591 is a phase 1/2 stage product being developed by Merck for Coronavirus Disease (COVID-19). The current trial status is terminated. This product is registered under clinical trial identifier NCT04498247. Target conditions include Coronavirus Disease (COVID-19).

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT04498247Phase 1/2Terminated

Competing Products

20 competing products in Coronavirus Disease (COVID-19)

See all competitors
ProductCompanyStageHype Score
Isavuconazonium Injection [Cresemba] + PlaceboAstellas PharmaPhase 3
77
bamlanivimab 7000mg + BRII-196+BRII-198 + AZD7442 (IV) + AZD7442 (IM) + SNG001 + Camostat + BMS-986414 + BMS-986413 + SAB-185 (3,840 Units/kg) + SAB-185 (10,240 Units/kg) + CASIRIVIMAB + IMDEVIMAB + Placebo for Bamlanivimab 7000mg + Placebo for Bamlanivimab 700mg + Placebo for BRII-196+BRII-198 + Placebo for SNG001 + Placebo for Camostat + Placebo for SAB-185 (low dose) + Placebo for BMS-986414 + BMS-986413 + Placebo for AZD7442 (IV) + Placebo for AZD7442 (IM) + Placebo for SAB-185 (high dose) + bamlanivimab 700mgEli LillyPhase 2/3
65
EQ001 + EQ001 PlaceboBioconPhase 3
77
Mesenchymal stem cellRohto PharmaceuticalPhase 1
33
ABBV-47D11 + Placebo for ABBV-47D11 + ABBV-2B04 + Placebo for ABBV-2B04AbbViePhase 1
33
Ibrutinib + PlaceboAbbViePhase 2
52
600 mg AZD7442 IV + 600mg placebo IVAstraZenecaPhase 2
52
EVUSHELDAstraZenecaPre-clinical
23
AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061]) + AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061])AstraZenecaPhase 2
52
AZD7442 IM + Placebo IM + AZD7442 IM + Placebo IM + AZD7442 IV + Placebo IV + AZD7442 IV + Placebo IVAstraZenecaPhase 1
33
Molnupiravir + PlaceboMerckPhase 3
77
Molnupiravir + PlaceboMerckPhase 2/3
65
V590MerckPhase 1
33
Molnupiravir + PlaceboMerckPhase 2/3
65
Efprezimod alfa + PlaceboMerckPhase 3
77
M5049 + M5049 + PlaceboMerckPhase 2
52
Molnupiravir + PlaceboMerckPhase 3
77
Frespaciguat + PlaceboMerckPhase 1
33
Canakinumab + PlaceboNovartisPhase 3
77
Ruxolitinib + FostamatinibNovartisPhase 1/2
41

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85